Indaptus Therapeutics, Inc.
INDP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001857044
No open-market purchases or sales by Indaptus Therapeutics, Inc. insiders were filed in the last 90 days; 9 institutions reported holding it in 13F filings for Q2 2026, worth $1.15M in total; no superinvestor holds it.
Q3 2023 vs. Q2 2023
How the institutions holding Indaptus Therapeutics, Inc. changed between Q2 2023 and Q3 2023.
All holders in Q3 2023All holders in Q2 2023
| Measure | Q2 2023 | Q3 2023 | Change |
|---|---|---|---|
| Holders | 15 | 16 | +1 |
| Shares | 583.7K | 570.5K | −13.2K (−2.3%) |
| Value | $1.11M | $1.57M | +$459.4K (+41.4%) |
New holders (2)
Institutions that held Indaptus Therapeutics, Inc. at the end of Q3 2023 but not at the end of Q2 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| JPMorgan Chase & Co | 7 | $19 | 0.00% |
| Qube Research & Technologies Ltd | 1 | $3 | 0.00% |
Sold out (1)
Institutions that held Indaptus Therapeutics, Inc. at the end of Q2 2023 and filed for Q3 2023 without it.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| Northern Trust Corp | 12,918 | $24.7K |